Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death Academic Article uri icon


MeSH Major

  • Antigens, CD36
  • Astrocytes
  • Cicatrix
  • Gliosis
  • Stroke


  • © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim In recent years there has been a clear consensus that neurodegenerative conditions can be better treated through concurrent modulation of different targets. Herein we report that combined inhibition of transglutaminase 2 (TG2) and histone deacetylases (HDACs) synergistically protects against toxic stimuli mediated by glutamate. Based on these findings, we designed and synthesized a series of novel dual TG2–HDAC binding agents. Compound 3 [(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide] emerged as the most interesting of the series, being able to inhibit TG2 and HDACs both in vitro (TG2 IC 50 =13.3±1.5 μm, HDAC1 IC 50 =3.38±0.14 μm, HDAC6 IC 50 =4.10±0.13 μm) and in cell-based assays. Furthermore, compound 3 does not exert any toxic effects in cortical neurons up to 50 μm and protects neurons against toxic insults induced by glutamate (5 mm) with an EC 50 value of 3.7±0.5 μm.

publication date

  • February 6, 2018



  • Academic Article



  • eng

Digital Object Identifier (DOI)

  • 10.1002/cmdc.201700601

PubMed ID

  • 29286587

Additional Document Info

start page

  • 227

end page

  • 230


  • 13


  • 3